Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.

Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW.

Neuropsychopharmacology. 2013 Jul;38(8):1557-65. doi: 10.1038/npp.2013.54. Epub 2013 Feb 26.

2.

Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.

Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M.

Psychopharmacology (Berl). 2016 Jul;233(13):2469-78. doi: 10.1007/s00213-016-4298-6. Epub 2016 Apr 16.

3.

Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.

Bedi G, Cooper ZD, Haney M.

Addict Biol. 2013 Sep;18(5):872-81. doi: 10.1111/j.1369-1600.2011.00427.x. Epub 2012 Jan 19.

4.

Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.

Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW.

Psychopharmacology (Berl). 2008 Mar;197(1):157-68. Epub 2007 Dec 27.

5.

A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.

Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M.

Addict Biol. 2013 Nov;18(6):993-1002. doi: 10.1111/j.1369-1600.2012.00461.x. Epub 2012 Jun 28.

6.

Marijuana withdrawal in humans: effects of oral THC or divalproex.

Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW.

Neuropsychopharmacology. 2004 Jan;29(1):158-70.

7.

Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.

Milman G, Bergamaschi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, Huestis MA.

Ther Drug Monit. 2014 Apr;36(2):218-24. doi: 10.1097/FTD.0b013e3182a5c446.

8.

Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.

Lile JA, Kelly TH, Hays LR.

Drug Alcohol Depend. 2011 Jul 1;116(1-3):86-92. doi: 10.1016/j.drugalcdep.2010.11.019. Epub 2011 Jan 11.

9.

Nefazodone decreases anxiety during marijuana withdrawal in humans.

Haney M, Hart CL, Ward AS, Foltin RW.

Psychopharmacology (Berl). 2003 Jan;165(2):157-65. Epub 2002 Nov 19.

PMID:
12439626
10.

Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse.

Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, Foltin RW.

Psychopharmacology (Berl). 2010 Aug;211(2):233-44. doi: 10.1007/s00213-010-1888-6. Epub 2010 Jun 3.

11.

Effects of oral THC maintenance on smoked marijuana self-administration.

Hart CL, Haney M, Ward AS, Fischman MW, Foltin RW.

Drug Alcohol Depend. 2002 Aug 1;67(3):301-9.

PMID:
12127201
12.

The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.

Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D.

Drug Alcohol Depend. 2013 Feb 1;128(1-2):64-70. doi: 10.1016/j.drugalcdep.2012.08.001. Epub 2012 Aug 22.

13.

Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status.

Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD, Foltin RW.

Biol Psychiatry. 2013 Feb 1;73(3):242-8. doi: 10.1016/j.biopsych.2012.07.028. Epub 2012 Aug 29.

14.

Bupropion SR worsens mood during marijuana withdrawal in humans.

Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW.

Psychopharmacology (Berl). 2001 May;155(2):171-9.

PMID:
11401006
15.

Effects of smoked marijuana in healthy and HIV + marijuana smokers.

Haney M.

J Clin Pharmacol. 2002 Nov;42(11 Suppl):34S-40S. Review.

PMID:
12412834
16.

Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.

Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV.

Drug Alcohol Depend. 2011 Jul 1;116(1-3):142-50. doi: 10.1016/j.drugalcdep.2010.12.010. Epub 2011 Feb 18.

17.

Marijuana's dose-dependent effects in daily marijuana smokers.

Ramesh D, Haney M, Cooper ZD.

Exp Clin Psychopharmacol. 2013 Aug;21(4):287-93. doi: 10.1037/a0033661.

18.

Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study.

Bedi G, Foltin RW, Gunderson EW, Rabkin J, Hart CL, Comer SD, Vosburg SK, Haney M.

Psychopharmacology (Berl). 2010 Dec;212(4):675-86. doi: 10.1007/s00213-010-1995-4. Epub 2010 Sep 8.

19.

Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans.

Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW.

Psychopharmacology (Berl). 2002 Dec;164(4):407-15. Epub 2002 Sep 14.

PMID:
12457271
20.

Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.

Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, Nunes EV, Bisaga A, Dakwar E, Carpenter KM, Sullivan MA, Choi JC.

Drug Alcohol Depend. 2016 Feb 1;159:53-60. doi: 10.1016/j.drugalcdep.2015.11.025. Epub 2015 Nov 27.

Supplemental Content

Support Center